| 1399 |
National Cancer Institute |
Html |
en |
Nausea and Vomiting Related to Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about nausea and vomiting as complications of cancer or its treatment. Approaches to the management of nausea and vomiting are discussed. |
| cancer treatment | 0.379171 |
| chemotherapy session | 0.416704 |
| past chemotherapy treatments | 0.404595 |
| motion sickness | 0.3776 |
| chemotherapy | 0.552867 |
| PDQ cancer information | 0.463652 |
| chemotherapy treatment | 0.441369 |
| late nausea | 0.506038 |
| anticipatory nausea | 0.711385 |
| clinical trials | 0.378644 |
| vomiting | 0.900093 |
| Vomiting Related | 0.471509 |
| cancer information summary | 0.41736 |
| patients | 0.393418 |
| earlier chemotherapy session | 0.400031 |
| treatment room | 0.360635 |
| NCI’s PDQ | 0.353745 |
| nausea | 0.98576 |
| NCI PDQ cancer | 0.3835 |
| radiation therapy | 0.495467 |
| antinausea drugs | 0.406187 |
| involuntary body functions | 0.353798 |
| certain chemotherapy drugs | 0.416814 |
| following treatment factors | 0.366128 |
|
| radiation therapy treatments | 0.356798 |
| treatment | 0.558325 |
| gastrointestinal tract | 0.416866 |
| following table | 0.366172 |
| delayed nausea | 0.530808 |
| Cancer Information Service | 0.360675 |
| following patient factors | 0.352013 |
| previous chemotherapy sessions | 0.394908 |
| patient | 0.370352 |
| treatment clinical trials | 0.357831 |
| National Cancer Institute | 0.420163 |
| Palliative Care Editorial | 0.381728 |
| new treatment | 0.358991 |
| chronic nausea | 0.490418 |
| drugs | 0.426328 |
| Cancer Care page | 0.352418 |
| Care Editorial Board | 0.382615 |
| chemotherapy sessions | 0.400414 |
| PDQ summary | 0.40058 |
| Nausea section | 0.481663 |
| cancer information summaries | 0.360345 |
| comprehensive cancer information | 0.360198 |
| cancer therapy | 0.357442 |
| acute nausea | 0.484601 |
|
CLICK HERE |
| 1546 |
National Cancer Institute |
Html |
en |
AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of AIDS-Related Lymphoma. |
| cancer treatment | 0.383886 |
| AIDS-Related Lymphoma Treatment | 0.393286 |
| cancer spreads | 0.326687 |
| malignant tumor cells | 0.309541 |
| body | 0.433918 |
| chemotherapy | 0.309155 |
| PDQ cancer information | 0.394743 |
| clinical trial search | 0.3032 |
| white blood cells | 0.3776 |
| clinical trials | 0.731846 |
| cancer information summary | 0.354741 |
| clinical trial | 0.454136 |
| AIDS-related peripheral/systemic lymphoma | 0.466219 |
| patients | 0.380662 |
| blood cells | 0.399358 |
| old blood cells | 0.295369 |
| AIDS-related lymphomas | 0.315773 |
| treatment clinical trial | 0.296684 |
| NCI PDQ cancer | 0.309251 |
| lymph nodes | 0.464743 |
| large B-cell lymphoma | 0.331734 |
| radiation therapy | 0.344733 |
| Treatment Editorial Board | 0.312981 |
| lymph node groups | 0.478813 |
| treatment | 0.574951 |
|
| swollen lymph nodes | 0.339153 |
| cancer cells | 0.476016 |
| lymph node group | 0.321747 |
| specific cancer cells | 0.306685 |
| AIDS-related non-Hodgkin lymphoma | 0.392687 |
| primary cns lymphoma | 0.430113 |
| treatment clinical trials | 0.33124 |
| National Cancer Institute | 0.355357 |
| aids-related lymphoma | 0.927549 |
| lymph vessels | 0.351707 |
| new treatment | 0.337577 |
| External radiation therapy | 0.327164 |
| B-cell immunoblastic lymphoma | 0.332379 |
| AIDS-related primary CNS | 0.358458 |
| bone marrow | 0.523968 |
| cancer clinical trials | 0.341952 |
| stage | 0.313358 |
| treatment options | 0.307053 |
| nervous system lymphoma | 0.295273 |
| cancer | 0.766753 |
| standard treatment | 0.309541 |
| lymph tissue | 0.333823 |
| body lymphoma | 0.323497 |
| Burkitt-like lymphoma | 0.311372 |
|
CLICK HERE |
| 1569 |
National Cancer Institute |
Html |
en |
Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of mycosis fungoides (including Sézary Syndrome). |
| red blood cells | 0.477836 |
| cancer treatment | 0.542958 |
| body | 0.529399 |
| type | 0.500535 |
| mycosis fungoides | 0.975868 |
| electron beam radiation | 0.477517 |
| PDQ cancer information | 0.525493 |
| clinical trial search | 0.486291 |
| white blood cells | 0.528751 |
| abnormal blood cells | 0.470219 |
| clinical trials | 0.793086 |
| Natural killer cells | 0.470828 |
| cancer information summary | 0.501852 |
| clinical trial | 0.600812 |
| mycosis fungoides cells | 0.530781 |
| patients | 0.476603 |
| blood cells | 0.579852 |
| skin electron beam | 0.532192 |
| malignant tumor cells | 0.48923 |
| NCI PDQ cancer | 0.469777 |
| Treatment Option Overview | 0.471891 |
| total skin electron | 0.534719 |
| radiation therapy | 0.663697 |
| Treatment Editorial Board | 0.471648 |
| beam radiation therapy | 0.484689 |
|
| treatment | 0.659413 |
| myeloid stem cell | 0.465408 |
| immature blood cells | 0.46931 |
| photodynamic therapy | 0.471883 |
| Recurrent mycosis fungoides | 0.52314 |
| mycosis fungoides spreads | 0.498418 |
| skin | 0.583221 |
| cancer cells | 0.698589 |
| lymphoid stem cell | 0.465897 |
| treatment clinical trials | 0.487816 |
| blood stem cells | 0.499083 |
| National Cancer Institute | 0.538216 |
| sézary syndrome | 0.849117 |
| normal cells | 0.5004 |
| new treatment | 0.509312 |
| Skin Cancer Treatment | 0.502202 |
| External radiation therapy | 0.473547 |
| metastatic mycosis fungoides | 0.5 |
| non-hodgkin lymphoma | 0.536949 |
| bone marrow | 0.486285 |
| cancer clinical trials | 0.50691 |
| stage | 0.517644 |
| cancer | 0.856203 |
| information | 0.542975 |
|
CLICK HERE |
| 1585 |
National Cancer Institute |
Html |
en |
Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version |
Multiple myeloma, plasmacytoma, lymphoplasmacytic lymphoma, and monoclonal gammopathy of undetermined significance (MGUS) are different types of plasma cell neoplasms. Find out about risk factors, symptoms, tests to diagnose, prognosis, stages, and treatment for these diseases. |
| red blood cells | 0.474629 |
| myeloma cells | 0.443938 |
| cancer treatment | 0.407402 |
| Myeloma treatment options | 0.373753 |
| biologic therapy | 0.382101 |
| blood -forming cells | 0.372128 |
| body | 0.40943 |
| type | 0.393577 |
| PDQ cancer information | 0.415525 |
| bone marrow aspiration | 0.378402 |
| clinical trial search | 0.419003 |
| white blood cells | 0.422631 |
| clinical trials | 0.689828 |
| mature blood cells | 0.378353 |
| abnormal plasma cells | 0.479263 |
| cancer information summary | 0.39289 |
| clinical trial | 0.492432 |
| stem cells | 0.378 |
| multiple myeloma | 0.975001 |
| patients | 0.39195 |
| blood cells | 0.516713 |
| plasma cell neoplasm | 0.43097 |
| radiation therapy | 0.450659 |
| Treatment Editorial Board | 0.365249 |
| General information | 0.366352 |
|
| treatment | 0.57038 |
| skeletal bone survey | 0.42368 |
| immature blood cells | 0.371472 |
| plasma cell tumor | 0.384236 |
| NCI-supported cancer | 0.3737 |
| cancer cells | 0.440163 |
| normal blood cells | 0.369334 |
| specific cancer cells | 0.38023 |
| diagnose multiple myeloma | 0.381187 |
| patient | 0.372697 |
| treatment clinical trials | 0.388849 |
| National Cancer Institute | 0.392841 |
| initial treatment | 0.372799 |
| new treatment | 0.406543 |
| plasma cells | 0.480204 |
| refractory multiple myeloma | 0.365057 |
| bone marrow | 0.582695 |
| healthy blood cells | 0.378266 |
| cells | 0.557939 |
| cancer clinical trials | 0.42623 |
| cancer | 0.627272 |
| information | 0.418087 |
| myeloma cells increases | 0.397071 |
| plasma cell neoplasms | 0.895903 |
|
CLICK HERE |
| 1638 |
National Cancer Institute |
Html |
en |
Essiac/Flor Essence (PDQ®)–Patient Version |
Essiac and Flor Essence are herbal tea mixtures first developed in Canada that are thought to remove toxins and poisons from the body and strengthen the immune system, although this has not been proven in cancer patients. Read about the history of Essiac and Flor Essence, the theory behind its use, and the results of laboratory, animal, and human studies. |
| Essiac formula | 0.502569 |
| peer-reviewed scientific journals | 0.490423 |
| cancer treatment | 0.454247 |
| cancer prevention | 0.375568 |
| Complementary Therapies Editorial | 0.416551 |
| Kill cancer cells | 0.376017 |
| breast cancer patient | 0.382628 |
| Drug Administration | 0.400504 |
| Cancer Information Specialist | 0.387931 |
| Flor Essence | 0.977313 |
| Flor Essence state | 0.48205 |
| herbal dietary supplements | 0.446297 |
| Flor Essence formulas | 0.482148 |
| Cancer Information Service | 0.448298 |
| Essiac | 0.851494 |
| Essiac herbal teas | 0.514938 |
| PDQ cancer information | 0.515287 |
| health tonics | 0.425459 |
| Cancer Complementary | 0.397385 |
| Flor Essence products | 0.478002 |
| CAM therapies | 0.376991 |
| prostate cancer cells | 0.376887 |
| Flor Essence tea | 0.479505 |
| National Cancer Institute | 0.598699 |
|
| studies | 0.410222 |
| Sloan-Kettering Cancer Center | 0.381887 |
| clinical trials | 0.491591 |
| Royal Cancer Commission | 0.384396 |
| alternative medicine | 0.441037 |
| health care | 0.376403 |
| cancer information summary | 0.466243 |
| alternative cancer therapies | 0.394811 |
| Federal Trade Commission | 0.379856 |
| clinical trial | 0.417042 |
| cancer cells | 0.389663 |
| Essiac/Flor Essence | 0.431725 |
| CAM cancer research | 0.383472 |
| herbal tea mixtures | 0.394707 |
| cancer patients | 0.424798 |
| NCI PDQ cancer | 0.416273 |
| cancer information database | 0.392781 |
| effects | 0.382227 |
| alternative therapies | 0.415163 |
| cancer information summaries | 0.394001 |
| Therapies Editorial Board | 0.400185 |
| cancer | 0.660273 |
| research studies | 0.398662 |
|
CLICK HERE |
| 1685 |
National Cancer Institute |
Html |
en |
Cannabis and Cannabinoids (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the use of Cannabis and cannabinoids in the treatment of cancer-related side effects, such as nausea and vomiting. |
| cannabinoid receptor CB2 | 0.721549 |
| cancer cell proliferation | 0.723514 |
| opioid-treated cancer patients | 0.721253 |
| lung cancer | 0.774703 |
| testicular germ cell | 0.736506 |
| Cannabis trials | 0.713054 |
| endogenous cannabinoids | 0.733591 |
| bladder cancer | 0.72104 |
| clinical trials | 0.71653 |
| cannabinoid receptors | 0.745589 |
| advanced cancer patients | 0.745457 |
| CBD oromucosal spray | 0.730536 |
| cancer cell invasiveness | 0.726743 |
| Cancer Res | 0.716198 |
| cancer patients | 0.801404 |
| Investigational New Drug | 0.714731 |
| non-small cell lung | 0.751006 |
| effects | 0.733811 |
| colorectal cancer cell | 0.727697 |
| cancer chemotherapy | 0.737056 |
| cannabinoids | 0.838589 |
| et al. | 0.767053 |
| treatment | 0.713465 |
| study | 0.761272 |
| CBD | 0.77215 |
|
| United States | 0.780596 |
| Cannabis plant | 0.728018 |
| orally administered Cannabis | 0.721336 |
| Cancer Epidemiol Biomarkers | 0.717008 |
| cancer cell lines | 0.803788 |
| cannabinoid receptor | 0.74565 |
| THC | 0.76674 |
| Cannabis extract | 0.739506 |
| lung cancer chemotherapy | 0.709535 |
| cancer cell invasion | 0.72445 |
| breast cancer cell | 0.789227 |
| Cancer pain results | 0.7118 |
| cancer pain | 0.721348 |
| open-label extension study | 0.709343 |
| advanced cancer | 0.748132 |
| cell death | 0.806928 |
| Abstract | 0.744659 |
| cannabis | 0.92504 |
| germ cell tumors | 0.735413 |
| medicinal Cannabis | 0.751597 |
| cell lung cancer | 0.728336 |
| Cannabis species | 0.726958 |
| cancer | 0.952946 |
| Guidelines recommend cannabinoids | 0.714742 |
|
CLICK HERE |
| 1810 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de páncreas (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de páncreas. |
| resectable pancreatic | 0.421757 |
| Sin embargo | 0.468358 |
| largo plazo | 0.439685 |
| chemotherapy following curative | 0.48776 |
| Tumor Study Group | 0.478506 |
| curative resection | 0.550476 |
| fase iii | 0.665649 |
| Natl Cancer Inst | 0.419755 |
| after curative resection | 0.455925 |
| Arch Surg | 0.451242 |
| effective adjuvant combined | 0.42796 |
| gemcitabina versus | 0.464125 |
| quimiorradioterapia posoperatoria | 0.420132 |
| Gastrointestinal Intergroup | 0.4265 |
| Cameron JL | 0.507923 |
| periampullary region | 0.42716 |
| patients with | 0.44756 |
| randomized controlled | 0.421891 |
| Conlon KC | 0.442167 |
| Lillemoe KD | 0.42689 |
| EORTC gastrointestinal tract | 0.428698 |
| meses vs | 0.421884 |
| gastrointestinal tract | 0.431387 |
| following curative resection | 0.474649 |
| Yeo CJ | 0.5451 |
|
| M0 T2 | 0.428111 |
| M0 T1 | 0.424975 |
| chemotherapy after resection | 0.463442 |
| Regine WF | 0.420404 |
| M0 T3 | 0.428453 |
| pancreatic cancer | 0.97706 |
| as risk factors | 0.421112 |
| postoperative adjuvant chemoradiation | 0.455288 |
| versus gemcitabina | 0.456328 |
| Surg Oncol | 0.435512 |
| patients with resected | 0.42485 |
| Gastrointestinal Tumor Study | 0.48648 |
| páncreas estadio | 0.439198 |
| régimen off | 0.443587 |
| Grochow LB | 0.426604 |
| estadio iii | 0.623435 |
| Abrams RA | 0.46019 |
| Gy XRT | 0.450407 |
| Adjuvant chemotherapy with | 0.456373 |
| Stocken DD | 0.455773 |
| Oncology Group | 0.420611 |
| adjuvant combined | 0.442249 |
| quimioterapia posoperatoria | 0.432032 |
| 5-fluorouracil after curative | 0.42675 |
|
CLICK HERE |
| 2035 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de próstata (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre los factores que pueden influir en el riesgo de cáncer de próstata y sobre la investigación dirigida a la prevención de esta enfermedad. |
| Cancer Events Trial | 0.485531 |
| principal hormona | 0.450019 |
| hiperplasia prostática benigna | 0.693996 |
| siguientes aspectos | 0.54196 |
| voluntarios sanos | 0.443459 |
| sistema urinario masculino | 0.492083 |
| protección baje | 0.460121 |
| sexuales masculinas | 0.54225 |
| caracterÃsticas sexuales masculinas | 0.494615 |
| productos lácteos | 0.532437 |
| National Cancer Institute | 0.461613 |
| causa problemas | 0.446148 |
| siguientes riesgos | 0.444876 |
| alto contenido | 0.439101 |
| vitamina e | 0.679303 |
| Instituto Nacional | 0.499716 |
| hormonas masculinas | 0.456898 |
|
| hormonas sexuales masculinas | 0.490983 |
| Cancer Prevention Trial | 0.881744 |
| próstata.ampliar próstata | 0.748136 |
| ensayo pcpt | 0.447994 |
| siguientes factores | 0.946442 |
| Physician Data Query | 0.60903 |
| Estados Unidos | 0.553599 |
| suficiente ejercicio | 0.453444 |
| prevención revisa | 0.462505 |
| Antecedentes familiares | 0.554865 |
| PDQ Prevención | 0.512729 |
| aparato reproductor masculino | 0.494928 |
| Prostate Cancer Prevention | 0.495264 |
| suficiente folato | 0.56107 |
| Prostate Cancer | 0.530877 |
| siguientes sumarios | 0.505076 |
|
CLICK HERE |
| 2111 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de esófago (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de esófago. |
| PDQ Exámenes | 0.728989 |
| Physician Data Query | 0.906997 |
| libre uso | 0.636785 |
| prevención revisa | 0.652274 |
| información ayuda | 0.682663 |
| vÃas respiratorias | 0.673206 |
|
| carcinoma epidermoide | 0.760269 |
| National Cancer Institute | 0.66546 |
| cáncer.ampliar esofagoscopÃa | 0.714851 |
| siguientes riesgos | 0.649549 |
| siguientes sumarios | 0.849506 |
| Instituto Nacional | 0.740034 |
|
CLICK HERE |
| 17289 |
National Cancer Institute |
Html |
es |
Servicios de apoyo |
Servicios disponibles para ayudarle a superar problemas durante el tratamiento del cáncer y después del mismo. |
|
|
CLICK HERE |